Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

There is concern about a potential ban on finasteride and dutasteride in the EU, with users discussing the impact on hair loss treatment. Some suggest alternative treatments or express skepticism about the likelihood of a ban.

Finasteride is more accepted than hair systems because it is less visible and maintains natural hair. Treatments like minoxidil and finasteride are commonly used for hair loss, but opinions on hair systems vary.

HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.